Daniel S. Levine

Daniel S. Levine is editor of Rare Daily. You can contact him by sending email to editor@globalgenes.org

Gene Therapy Developer LogicBio Raises $70 Million in IPO
Gene Therapy Developer LogicBio Raises $70 Million in IPO Rare Daily Staff LogicBio Therapeutics, a genome editing company focused on… Continue Reading
GenSight Biologics Reports Positive Data from Late-Stage Gene Therapy Trial in Rare Eye Disease
Rare Daily Staff GenSight Biologics reported positive results from its late-stage clinical trial, which evaluates the safety and efficacy of… Continue Reading
The CMT Research Foundation Expands Scientific Advisory Board
Rare Daily Staff The CMT Research Foundation, which is focused on delivering treatments and cures for Charcot-Marie-Tooth disease, said it… Continue Reading
Why Rare Disease Drug Developers Need Regular Interaction with the FDA
Despite accelerated pathways for the development and approval of rare disease therapies, significant challenges remain for companies wishing… Continue Reading
Abeona Therapeutics Appoints New CMO
Rare Daily Staff Abeona Therapeutics said it appointed João Siffert, an industry veteran with medical and academic experience, as head of… Continue Reading
AveXis Submits SMA Gene Therapy for Regulatory Approval in U.S., Europe, and Japan
Rare Daily Staff AveXis, in a letter addressed to the spinal muscular atrophy community, said it submitted regulatory applications in the… Continue Reading
Rare Leader: Dawn Ireland, President, CDH International
The Basics Name: Dawn Ireland Title: President Organization: CDH International Disease focus: Congenital diaphragmatic hernia is a birth… Continue Reading

Follow us on Twitter